Takeda Pharmaceutical Co. Ltd. has entered into numerous company and academic partnerships over the past year or so as it has strived to rebuild its R&D pipeline, but this level of feverish deal activity may soon be coming to an end.
"We don’t intend to keep this pace up forever," says chief medical and scientific officer Andrew Plump. "We have a...








